Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
Bonnefoi, H., Litière, S., Piccart, M., MacGrogan, G., Fumoleau, P., Brain, E., Petit, T., Rouanet, P., Jassem, J., Moldovan, C., Bodmer, A., Zaman, K., Cufer, T., Campone, M., Luporsi, E., Malmström, P., Werutsky, G., Bogaerts, J., Bergh, J., Cameron, D.A.
Published in Annals of oncology (01.06.2014)
Published in Annals of oncology (01.06.2014)
Get full text
Journal Article
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study
Bonnefoi, H., Jacot, W., Saghatchian, M., Moldovan, C., Venat-Bouvet, L., Zaman, K., Matos, E., Petit, T., Bodmer, A., Quenel-Tueux, N., Chakiba, C., Vuylsteke, P., Jerusalem, G., Brain, E., Tredan, O., Messina, C.G.M., Slaets, L., Cameron, D.
Published in Annals of oncology (01.02.2015)
Published in Annals of oncology (01.02.2015)
Get full text
Journal Article
Web Resource
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
HOTTINGER, A. F, AISSA, A. B, BODMER, A, DIETRICH, P.-Y, ESPELI, V, SQUIBAN, D, DUNKEL, N, VARGAS, M. I, HUNDSBERGER, T, MACH, N, SCHALLER, K, WEBER, D. C
Published in British journal of cancer (27.05.2014)
Published in British journal of cancer (27.05.2014)
Get full text
Journal Article
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
Hottinger, A F, Ben Aissa, A, Espeli, V, Squiban, D, Dunkel, N, Vargas, M I, Hundsberger, T, Mach, N, Schaller, K, Weber, D C, Bodmer, A, Dietrich, P-Y
Published in British journal of cancer (20.03.2018)
Published in British journal of cancer (20.03.2018)
Get full text
Journal Article
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Friedlaender, A., Vuillemier, A., Viassolo, V., Ayme, A., De Talhouet, S., Combes, J.-D., Peron, J., Bodmer, A., Giraud, S., Buisson, A., Bonadona, V., Gauchat-Bouchardy, I., Tredan, O., Chappuis, P., Labidi-Galy, S.I.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Evaluating the Patient with Left Lower Quadrant Abdominal Pain
Bodmer, Nicholas A, Thakrar, Kiran H
Published in The Radiologic clinics of North America (01.11.2015)
Published in The Radiologic clinics of North America (01.11.2015)
Get more information
Journal Article
P241 Usefulness of the 21-gene assay to guide adjuvant chemotherapy decision-making: Geneva experience
Bodmer, A, Hugli, A, Berger, S. Diebold, Favet, L, Alberto, M. Guetty, Exquis, B
Published in Breast (Edinburgh) (01.03.2015)
Published in Breast (Edinburgh) (01.03.2015)
Get full text
Journal Article
Acute Normovolemic Hemodilution in the Pig Is Associated with Renal Tissue Edema, Impaired Renal Microvascular Oxygenation, and Functional Loss
Konrad, Franziska M, Mik, Egbert G, Bodmer, Sander I A, Ates, N Bahar, Willems, Henriëtte F. E M, Klingel, Karin, de Geus, Hilde R H, Stolker, Robert Jan, Johannes, Tanja
Published in Anesthesiology (Philadelphia) (01.08.2013)
Published in Anesthesiology (Philadelphia) (01.08.2013)
Get full text
Journal Article
Microvascular and mitochondrial PO2 simultaneously measured by oxygen-dependent delayed luminescence
Bodmer, Sander I. A., Balestra, Gianmarco M., Harms, Floor A., Johannes, Tanja, Raat, Nicolaas J. H., Stolker, Robert J., Mik, Egbert G.
Published in Journal of biophotonics (01.02.2012)
Published in Journal of biophotonics (01.02.2012)
Get full text
Journal Article
Adjuvant pertuzumab (PER) for HER2-positive early stage breast cancer (eBC): A Swiss experience
Stravodimou, A., Bodmer, A., Aedo Lopez, V., Zurcher, J.P., Zaman, K.
Published in European journal of cancer (1990) (01.04.2018)
Published in European journal of cancer (1990) (01.04.2018)
Get full text
Journal Article
268P Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple-negative, EGFR positive breast cancer: A multicenter single arm phase II trial [SAKK 24/14]
Wicki, A., Mamot, C., Hasler-Strub, U., Riniker, S., Li, Q., Holer, L., Baertschi, D., Zaman, K., von Moos, R., Dedes, K.J., Novak, U., Bodmer, A., Ritschard, R., Obermann, E., Ackermann, C.J., Membrez-Antonioli, V., Zuerrer, U., Caspar, C.B., Rochlitz, C., Winterhalder, R.C.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
238PBRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Friedlaender, A, Vuillemier, A, Viassolo, V, Ayme, A, De Talhouet, S, Combes, J-D, Peron, J, Bodmer, A, Giraud, S, Buisson, A, Bonadona, V, Gauchat-Bouchardy, I, Tredan, O, Chappuis, P, Labidi-Galy, S I
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Abstract P3-03-05: Association between BRCA1 and BRCA2 mutations and survival in breast cancer patients according to molecular subtype
Tredan, O, De Talhouet, S, Peron, J, Friedlaender, A, Vuilleumier, A, Viassolo, V, Ayme, A, Chappuis, PO, Buisson, A, Bonadona, V, Bodmer, A, Labidi-Galy, SI
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article
Erratum: Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
Hottinger, A F, Ben Aissa, A, Espeli, V, Squiban, D, Dunkel, N, Vargas, M I, Hundsberger, T, Mach, N, Schaller, K, Weber, D C, Bodmer, A, Dietrich, P-Y
Published in British journal of cancer (20.03.2018)
Published in British journal of cancer (20.03.2018)
Get full text
Journal Article
Abstract P1-18-01: Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE)
Müller, A, Templeton, AJ, Hayoz, S, Hawle, H, Hasler-Strub, U, Schwitter, M, Pestalozzi, BC, Pagani, O, Bützberger, P, Wehrhahn, T, Rauch, D, Inauen, R, Betticher, D, Zaman, K, Bodmer, A, Popescu, RA, Rothschild, S, Schardt, J, Borner, M, Fuhrer, A, Schär, C, Gillessen, S, von Moos, R
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article